

The effect of CMPX-2023 in the transplant model of psoriasis; in which a psoriatic lesion is induced in non-lesional skin transplanted onto immune-deficient (BNX) mice by injecting super-antigen activated peripheral blood cells intra-dermally into the transplant.

Published: 04-06-2013

Last updated: 25-04-2024

Is CMPX-2030 effective in the transplant model of psoriasis

| | |
|------------------------------|------------------------|
| Ethical review | Approved WMO |
| Status | Recruitment stopped |
| Health condition type | Other condition |
| Study type | Observational invasive |

Summary

ID

NL-OMON38996

Source

ToetsingOnline

Brief title

The effect of CMPX-2023 in the transplant psoriasis model

Condition

- Other condition
- Autoimmune disorders
- Epidermal and dermal conditions

Synonym

psoriasis

Health condition

een onderzoek naar werking van een middel in een model

Research involving

Human

Sponsors and support

Primary sponsor: Complix

Source(s) of monetary or material Support: Industry

Intervention

Keyword: psoriasis, skin, therapies, transplant

Outcome measures

Primary outcome

NA

Secondary outcome

NA

Study description

Background summary

Client wishes to know if CMPX-2023 is effective in the transplant model of psoriasis

Study objective

Is CMPX-2030 effective in the transplant model of psoriasis

Study design

Blood and skin biopsies are taken from patients with psoriasis vulgaris

Study burden and risks

Contacts

Public

Complix

Technologiepark 4

Gent 9051

BE

Scientific

Complix

Technologiepark 4

Gent 9051

BE

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Patients with light to mild psoriasis vulgaris

Exclusion criteria

-Volunteers cannot be treated systemically (for psoriasis)

Volunteers cannot have UV/light therapy

Volunteers cannot be taking immune-modulating drugs for other diseases

Volunteers should not have problems with the Köbner phenomenon.
-Volunteers with atopic dermatitis/eczematous skin conditions.
-Volunteers cannot be pregnant

Study design

Design

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Other

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 18-06-2013

Enrollment: 22

Type: Actual

Ethics review

Approved WMO

Date: 04-06-2013

Application type: First submission

Review commission: METC Leiden-Den Haag-Delft (Leiden)

metc-ldd@lumc.nl

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

| Register | ID |
|----------|----------------|
| CCMO | NL44176.098.13 |